This protocol combines CJC-1295 DAC, a long-acting growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue. Together, they stimulate the body's natural production of growth hormone and IGF-1 through complementary mechanisms. Dosing involves weekly CJC-1295 DAC injections and daily Ipamorelin injections, typically over 8-16 weeks.
- Combines two peptides for synergistic GH release.
- CJC-1295 DAC has an extended half-life, requiring weekly dosing.
- Ipamorelin selectively stimulates GH with minimal side effects.
- Administered via subcutaneous injections.
- Commonly used for body composition improvements.
Reconstitution
Vial strength
5 mg
Bacteriostatic water
2 mL
Concentration
2.5 mg/mL
CJC-1295 DAC: 1 unit = 0.01 mL = 25 mcg; Ipamorelin: 1 unit = 0.01 mL ≈ 16.7 mcg
- 1For CJC-1295 DAC: Draw 2.0 mL bacteriostatic water using a sterile syringe.
- 2For Ipamorelin: Draw 3.0 mL bacteriostatic water using a sterile syringe.
- 3Inject water slowly down the side of the vial, avoiding direct stream onto the powder or foaming.
- 4Gently swirl or roll the vial until the powder is fully dissolved (do not shake vigorously).
- 5Label each reconstituted vial with the date and refrigerate at 2–8 °C (35.6–46.4 °F).
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-2 | CJC-1295 DAC: 1000 mcg (1.0 mg) once weekly; Ipamorelin: 100 mcg (0.1 mg) once daily | CJC-1295 DAC: 40 units (0.40 mL); Ipamorelin: 6 units (0.06 mL) |
| Weeks 3-4 | CJC-1295 DAC: 1000 mcg (1.0 mg) once weekly; Ipamorelin: 150 mcg (0.15 mg) once daily | CJC-1295 DAC: 40 units (0.40 mL); Ipamorelin: 9 units (0.09 mL) |
| Weeks 5-12 | CJC-1295 DAC: 1000 mcg (1.0 mg) once weekly; Ipamorelin: 200 mcg (0.2 mg) once daily | CJC-1295 DAC: 40 units (0.40 mL); Ipamorelin: 12 units (0.12 mL) |
Protocol detail
| CJC-1295 DAC | Inject 1 mg (40 units) subcutaneously once per week on the same day each week. |
|---|---|
| Ipamorelin | Begin with 100 mcg (6 units) daily, gradually increasing to 200 mcg (12 units) by Week 5. |
| Timing | Administer Ipamorelin before bed to align with the body's natural nocturnal growth hormone pulses. |
| Cycle Length | A standard cycle is 8–12 weeks, which can be extended up to 16 weeks if well-tolerated. |
| Injection Sites | Consistently rotate injection areas among the abdomen, thighs, and upper arms. |
Overview at a glance
| Goal | Amplify the body's natural growth hormone and IGF-1 secretion by targeting both GHRH and ghrelin receptor pathways. |
|---|---|
| Schedule | CJC-1295 DAC administered once weekly, combined with Ipamorelin once daily, typically for 8–16 weeks. |
| CJC-1295 DAC Dose | 1–2 mg weekly (standard dose is 1 mg). |
| Ipamorelin Dose | 100–300 mcg daily, with a gradual increase during the initial weeks. |
| Storage | Lyophilized peptide should be frozen; reconstituted peptide must be refrigerated. Avoid freezing and thawing reconstituted solutions. |
How it works
CJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds to serum albumin, giving it an extended half-life of 6-8 days, leading to sustained increases in growth hormone and IGF-1. Ipamorelin, a selective ghrelin receptor agonist, triggers potent, pulsatile release of growth hormone without significantly affecting other hormones like ACTH or cortisol. When used together, these peptides activate distinct yet complementary pathways. This synergistic action leads to a more pronounced and amplified endogenous growth hormone secretion compared to using either peptide alone, promoting growth and repair processes.
Reported effects
- Improved lean body mass
- Reduced fat mass
- Sustained elevation of GH and IGF-1
- Selective GH release without increased cortisol
- Generally well-tolerated
Reported side effects
- Injection-site reactions (transient)
- Water retention (mild)
- Headache (mild)
- Transient numbness/tingling
Storage
Lyophilised (unmixed)
Store at ≤-15 °C (5 °F), preferably ≤-50 °C (-58 °F) for long-term storage.
After reconstitution
Refrigerate at 2-8 °C (35.6-46.4 °F); use within 3-4 weeks. Avoid repeated freeze-thaw cycles.
Supplies
| Peptide vials | For an 8-week cycle: 2x CJC-1295 DAC (5 mg) and 3x Ipamorelin (5 mg) vials. |
|---|---|
| Insulin Syringes (U-100) | Approximately 8 syringes per week (1 for CJC, 7 for Ipamorelin). Consider 30- or 50-unit syringes for Ipamorelin doses ≤10 units for better accuracy. |
| Bacteriostatic Water | For an 8-week cycle, approximately 13 mL needed (2 bottles of 10 mL). |
| Alcohol Swabs | Roughly 16 swabs per week (2 for each Ipamorelin injection + 2 for weekly CJC-1295 DAC). Consider 100-count boxes. |
Important notes
- Use a new sterile insulin syringe for each injection and dispose of it properly.
- Systematically rotate injection sites to prevent local irritation and lipohypertrophy.
- Inject slowly and wait a few seconds before withdrawing the needle.
- Keep CJC-1295 DAC and Ipamorelin in separate vials; do not pre-mix solutions.
- This guide is for educational purposes only and is not medical advice.
Frequently asked questions
Why are CJC-1295 DAC and Ipamorelin used together?
These peptides are stacked because they work through different but complementary pathways to stimulate growth hormone release. CJC-1295 DAC provides a sustained background of GHRH signaling, while Ipamorelin triggers pulsatile GH release, leading to a synergistic and more potent overall effect on GH levels.
Can I pre-mix CJC-1295 DAC and Ipamorelin in the same syringe?
No, it is important to keep CJC-1295 DAC and Ipamorelin in separate vials and not to pre-mix them in a single syringe before injection. They have different reconstitution volumes and dosing frequencies, and mixing them could affect their stability or efficacy.
What is the recommended injection timing for Ipamorelin?
Ipamorelin is commonly administered before bed. This timing is chosen to coincide with the body's natural nocturnal growth hormone pulses, potentially maximizing its effectiveness in stimulating GH secretion.
How long does a typical cycle of this stack last?
A standard cycle for the CJC-1295 DAC and Ipamorelin stack typically ranges from 8 to 12 weeks. Depending on individual response and tolerability, some protocols may extend up to 16 weeks.
Educational reference only. These figures summarise how CJC-1295 DAC + Ipamorelin Stack is commonly described in research literature and supplier documentation, including the CJC-1295 DAC + Ipamorelin Stack listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
CJC-1295 DAC + Ipamorelin Stack (CJC-1295 (2 mg) + Ipamorelin (5 mg))
Amplify growth hormone production with this synergistic peptide stack.
Sermorelin (5 mg Vial)
Stimulates natural growth hormone release, supporting physiological renewal and anabolism.
AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend)
A powerful blend for synergistic fat loss and growth hormone optimization.
CJC-1295 DAC (2 mg Vial)
Long-acting GHRH analog for sustained growth hormone release.